Flumazenil
Generic name
Flumazenil
Brand name
ATC Code
V03AB25
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
The half-life of flumazenil in children over 1 year of age is slightly shorter and varies more than in
adults, averaging 40 minutes (generally in the range 20 to 75 minutes). The
clearance and volume of distribution (corrected for bodyweight) are the same as for adults.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Antagonist for sedation cause by benzodiazepines and zopiclone |
|---|
|
Renal impaiment in children > 3 months
No information available on dose adjustment in renal impairment.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ALL OTHER THERAPEUTIC PRODUCTS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Antidotes | ||
|---|---|---|
| V03AB27 | ||
| V03AB16 | ||
| V03AB24 | ||
| V03AB33 | ||
| V03AB17 | ||
| V03AB15 | ||
| V03AB13 | ||
| V03AB19 | ||
| V03AB14 | ||
| V03AB06 | ||
| V03AB35 | ||
| Iron chelating agents | ||
|---|---|---|
| V03AC03 | ||
| V03AC02 | ||
| V03AC01 | ||
| Drugs for treatment of hyperkalemia and hyperphosphatemia | ||
|---|---|---|
| V03AE07 | ||
| V03AE01 | ||
| V03AE02 | ||
| V03AE01 | ||
| Detoxifying agents for antineoplastic treatment | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
| Drugs for treatment of hypoglycemia | ||
|---|---|---|
| V03AH01 | ||
| Other therapeutic products | ||
|---|---|---|
| V03AX03 | ||
| DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT | ||
|---|---|---|
| V03AF03 | ||
| V03AF01 | ||
| V03AF07 | ||
| OTHER THERAPEUTIC PRODUCTS | ||
|---|---|---|
| V03AX03 | ||
References
- Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
- SPC Flumazenil 0,1 mg/ml (08/05/2005), RVG 25920
- Hameln Pharma Plus, Flumazenil-hameln® 0,1 mg/ml Injektionslösung und Konzentrat zur Herstellung einer Infusionslösung (63155.00.00), 09/18
- Cheplapharma, Anexate® 0,5 mg/5 ml Injektionslösung (14747.00.00), 04/16
Changes
Therapeutic Drug Monitoring
Overdose
